DekaBank Deutsche Girozentrale trimmed its holdings in shares of UiPath Inc. (NYSE:PATH - Free Report) by 28.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 312,065 shares of the healthcare company's stock after selling 123,046 shares during the period. DekaBank Deutsche Girozentrale owned about 0.06% of UiPath worth $7,894,000 as of its most recent SEC filing.
A number of other hedge funds have also modified their holdings of PATH. HighMark Wealth Management LLC purchased a new stake in UiPath in the 4th quarter worth approximately $27,000. FNY Investment Advisers LLC purchased a new stake in UiPath in the 4th quarter worth approximately $40,000. Tyler Stone Wealth Management purchased a new stake in UiPath in the 2nd quarter worth approximately $28,000. FSC Wealth Advisors LLC purchased a new stake in UiPath in the 4th quarter worth approximately $43,000. Finally, Fifth Third Bancorp grew its stake in UiPath by 2,005.3% in the 3rd quarter. Fifth Third Bancorp now owns 2,000 shares of the healthcare company's stock worth $34,000 after acquiring an additional 1,905 shares during the period. 62.50% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several analysts have commented on the stock. Evercore ISI lifted their target price on shares of UiPath from $24.00 to $27.00 and gave the stock an "in-line" rating in a research note on Thursday, March 14th. KeyCorp initiated coverage on shares of UiPath in a research note on Monday. They set an "overweight" rating and a $27.00 price objective for the company. Canaccord Genuity Group boosted their price objective on shares of UiPath from $27.00 to $30.00 and gave the company a "buy" rating in a research note on Friday, March 15th. Truist Financial reissued a "buy" rating and set a $32.00 price objective on shares of UiPath in a research note on Wednesday, March 20th. Finally, Bank of America boosted their price objective on shares of UiPath from $26.00 to $30.00 and gave the company a "buy" rating in a research note on Thursday, March 14th. Nine research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $27.41.
Check Out Our Latest Stock Report on UiPath
Insiders Place Their Bets
In other news, CFO Ashim Gupta sold 16,000 shares of the business's stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $22.84, for a total value of $365,440.00. Following the completion of the sale, the chief financial officer now owns 87,505 shares of the company's stock, valued at approximately $1,998,614.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 72,000 shares of company stock worth $1,591,360 in the last quarter. 31.03% of the stock is owned by corporate insiders.
UiPath Trading Down 0.5 %
PATH stock traded down $0.10 during trading on Thursday, reaching $21.31. The stock had a trading volume of 6,341,481 shares, compared to its average volume of 9,122,140. UiPath Inc. has a 1-year low of $12.38 and a 1-year high of $27.87. The company has a market capitalization of $12.13 billion, a P/E ratio of -125.35 and a beta of 0.96. The firm has a fifty day moving average price of $23.35 and a 200 day moving average price of $21.33.
UiPath (NYSE:PATH - Get Free Report) last issued its quarterly earnings data on Wednesday, March 13th. The healthcare company reported $0.06 EPS for the quarter, topping analysts' consensus estimates of ($0.04) by $0.10. UiPath had a negative net margin of 6.87% and a negative return on equity of 3.29%. The firm had revenue of $405.25 million for the quarter, compared to analyst estimates of $383.32 million. Sell-side analysts predict that UiPath Inc. will post -0.04 EPS for the current year.
About UiPath
(
Free Report)
UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.
Further Reading
Before you consider UiPath, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UiPath wasn't on the list.
While UiPath currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
